0
0
0
0
1
2
3
$0
Is Johnson & Johnson solid or fragile? The Finex Financial Health Scanner reads JNJ's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $94.2B |
|---|---|
| Net income | $26.8B |
| Operating margin | 26.8% |
| Net margin | 28.5% |
| Cash and investments | $20.1B |
| Total debt | $47.9B |
| Free cash flow | $18.5B |
| Revenue growth (1 year) | 6.0% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.